Equipment House 9M 2022 net profit down 29% to SAR 42.8 mln; Q3 at SAR 8.7 mln

Equipment House 9M 2022 net profit down 29% to SAR 42.8 mln; Q3 at SAR 8.7 mln

06/11/2022 Argaam Exclusive

View other reports

Scientific and Medical Equipment House Co. (Equipment House) recorded a drop of 29% in net profit after Zakat and tax to SAR 42.8 million in the first nine months of 2022, from SAR 60 million in the year-ago period.



Financials (M)

Item 9m 2021 9m 2022 Change‬
Revenues 494.15 524.93 6.2 %
Gross Income 113.91 120.77 6.0 %
Operating Income 65.90 59.95 (9.0 %)
Net Income 60.07 42.87 (28.6 %)
Average Shares 30.00 30.00 -
EPS (Riyals) 2.00 1.43 (28.6 %)

The company recorded an increase of SAR 5.4 million year-on-year (YoY) in finance costs. Zakat and employees expenses increased by SAR 2.4 million and SAR 2.3 million YoY, respectively.

 

On the other hand, Equipment House reported a decline in its share of results in subsidiaries by SAR 4.8 million, with other income dropping by SAR 2.9 million YoY in the same period.



Current Quarter Comparison (M)

Compared With The
Item Q3 2021 Q3 2022 Change‬
Revenues 176.51 186.07 5.4 %
Gross Income 37.54 36.03 (4.0 %)
Operating Income 19.21 15.94 (17.1 %)
Net Income 16.97 8.79 (48.2 %)
Average Shares 30.00 30.00 -
EPS (Riyals) 0.57 0.29 (48.2 %)

In Q3 2022, net profit after Zakat and tax fell by 49% to SAR 8.7 million, from SAR 16.89 million in Q3 2021. The medical equipment supplier reported a rise in salaries and the like, due to higher number of employees enrolled in new projects compared to the same period last year. New roles and duties were created to boost the company’s business and support future expansion.

 

Equipment House reported an increase in expenses from Naqaa Co., related to an increase in the number of pharmacies (acquisition and transfer costs).

 

It also reported higher amortization of right-of-use assets (the new pharmacies in Naqaa). Higher financing interest and Zakat expenses also weighed on the third-quarter results.

 

Compared to Q2 2022, net profit slumped 49.8% from SAR 17.36 million.

 

Total shareholders’ equity, no minority interest, stood at SAR 496.3 million as of Sept. 30, 2022, compared to SAR 473.5 million in the year-earlier period.



Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2013 - - - - - -
Q2 2013 - - - - - -
Q3 2013 - - - - - -
Q4 2013 - - - - - -
Q1 2014 - - - - - -
Q2 2014 - - - - - -
Q3 2014 - - - - - -
Q4 2014 - - - - - -
Q1 2015 - - - - - -
Q2 2015 - - - - - -
Q3 2015 - - - - - -
Q4 2015 - - - - - -
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 151.56 - 32.66 - 19.39 -
Q2 2021 166.08 - 43.72 - 27.30 -
Q3 2021 176.51 - 37.54 - 19.21 -
Q4 2021 205.30 - 39.07 - 17.52 -
Q1 2022 162.56 7.3 % 37.92 16.1 % 21.84 12.7 %
Q2 2022 176.30 6.1 % 46.82 7.1 % 22.17 (18.8 %)
Q3 2022 186.07 5.4 % 36.03 (4.0 %) 15.94 (17.1 %)


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
Q1 2013 - - - - - -
Q2 2013 - - - - - -
Q3 2013 - - - - - -
Q4 2013 - - - - - -
Q1 2014 - - - - - -
Q2 2014 - - - - - -
Q3 2014 - - - - - -
Q4 2014 - - - - - -
Q1 2015 - - - - - -
Q2 2015 - - - - - -
Q3 2015 - - - - - -
Q4 2015 - - - - - -
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 19.19 - 0.64 3.74 15.45 0.52
Q2 2021 23.92 - 0.80 - 23.92 0.80
Q3 2021 16.97 - 0.57 - 16.97 0.57
Q4 2021 17.45 - 0.58 - 17.45 0.58
Q1 2022 16.73 (12.8 %) 0.56 - 16.73 0.56
Q2 2022 17.36 (27.4 %) 0.58 - 17.36 0.58
Q3 2022 8.79 (48.2 %) 0.29 - 8.79 0.29

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 - - -
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 21.87 % 13.81 % 10.55 %
Q1 2022 22.27 % 14.03 % 10.57 %
Q2 2022 22.39 % 13.20 % 9.51 %
Q3 2022 21.89 % 12.78 % 8.26 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2013 - - - -
Q2 2013 - - - -
Q3 2013 - - - -
Q4 2013 - - - -
Q1 2014 - - - -
Q2 2014 - - - -
Q3 2014 - - - -
Q4 2014 - - - -
Q1 2015 - - - -
Q2 2015 - - - -
Q3 2015 - - - -
Q4 2015 - - - -
Q1 2016 - - - -
Q2 2016 - - - -
Q3 2016 - - - -
Q4 2016 - - - -
Q1 2017 - - - -
Q2 2017 - - - -
Q3 2017 - - - -
Q4 2017 - - - -
Q1 2018 - - - -
Q2 2018 - - - -
Q3 2018 - - - -
Q4 2018 - - - -
Q1 2019 - - - -
Q2 2019 - - - -
Q3 2019 - - - -
Q4 2019 - - - -
Q1 2020 - - - -
Q2 2020 - - - -
Q3 2020 - - - -
Q4 2020 - - - -
Q1 2021 30.00 - - -
Q2 2021 30.00 - - 14.70
Q3 2021 30.00 - - -
Q4 2021 30.00 2.58 2.46 15.78
Q1 2022 30.00 2.50 2.50 16.34
Q2 2022 30.00 2.28 2.28 16.25
Q3 2022 30.00 2.01 2.01 16.54

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 - - -
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 21.32 21.32 3.27
Q2 2022 18.98 18.98 2.67
Q3 2022 21.69 21.69 2.64

Business Segments (Million)

Compared With The
Period Operation and maintenance Sales of medical devices and revenue from after-sales maintenance services Construction Medications and Medical Supplies Meat and Food Eliminations
Q1 2021 123.04 8.50 10.54 7.37 2.34 (0.22)
Q2 2021 137.92 8.50 10.44 8.00 2.87 (1.64)
Q3 2021 145.75 12.85 8.66 5.88 4.01 (0.65)
Q4 2021 164.19 33.17 20.44 (4.60) 1.30 (9.20)
Q1 2022 130.15 11.47 11.04 8.94 3.48 (2.51)
Q3 2022 144.11 11.32 15.37 14.70 1.19 (0.62)

Current
Market Cap (M Riyal) 1,563.00
Enterprise Value (EV) (M) 1,770.09
Shares Outstanding ((M)) 30.00
EPS ( Riyal) (TTM) 1.53
Book Value (BV) ( Riyal) 17.78
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 34.01
P/E (TTM) 34.01
Price/book 2.93
Return on Average Assets (%) (TTM) 4.3
Return on Average Equity (%) (TTM) 8.9

Share Price

Scientific and Medical Equipment House Co. (EQUIPMENT HOUSE)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.